on PharmaSGP Holding SE (isin : DE000A2P4LJ5)
PharmaSGP Holding SE Announces Delisting Offer by FUTRUE GmbH
PharmaSGP Holding SE has announced the commencement of the acceptance period for FUTRUE GmbH's public delisting tender offer. Shareholders have until August 11, 2025, to tender their shares in exchange for €28.00 per share. This move signifies a strategic step for the company as it considers transitioning away from public markets.
PharmaSGP specializes in over-the-counter pharmaceuticals focused on natural ingredients. The company has expanded its market presence across Europe, achieving significant revenue growth, reaching €118.8 million in 2024. This delisting forms part of FUTRUE GmbH's broader strategy to consolidate its holdings and streamline operations.
The tender offer and related documents can be accessed online, providing shareholders all necessary information. This development marks a pivotal moment for PharmaSGP, indicating potential realignment of its business focus.
R. E.
Copyright © 2025 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all PharmaSGP Holding SE news